Lingbin Meng

Assistant Professor

The Ohio State University Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Lingbin Meng is an Assistant Professor at The Ohio State University Comprehensive Cancer Center. His research primarily focuses on bladder cancer management, immunotherapy, and survival disparities in cancer patients. Recent articles highlight his work on neoadjuvant and adjuvant therapies, drug resistance in prostate cancer, and the impact of non-oncologic medication during radiotherapy. He is dedicated to advancing therapeutic approaches and understanding mechanisms in various malignancies.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (2)

Katharine A. Collier

UNITED STATES

View details

Haley Perlow

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lingbin Meng

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Evaluating the Impact of Common Non-Oncologic Medication Use During Radiotherapy in Patients with High-Risk Prostate Cancer

Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant Therapies and Biomarkers in Muscle Invasive Bladder Cancer.

Harnessing the power of combination therapy: reflecting on the final survival data from the CLEAR study with lenvatinib plus pembrolizumab.

Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies.

Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis.

CNPY2 drives DSS-induced colitis via the macrophage-ROS axis.

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.

CNPY2 in Solid Tumors: Mechanisms, Biomarker Potential, and Therapeutic Implications.

A novel TLR4 accessory molecule drives hepatic oncogenesis through tumor-associated macrophages.

Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies

Collaborators (2)

Katharine A. Collier

Haley Perlow

Make your next move.